Ad hoc data from KEYNOTE-905/EV-303 showed consistent efficacy contributions for both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC #blcsm #oncology
Read more from @myESMO #ESMO26: https://www.onclive.com/view/ad-hoc-analysis-supports-contributions-of-both-enfortumab-vedotin-and-pembrolizumab-in-cisplatin-ineligible-mibc
251 浏览 · 0 赞 · 0 转发 · 0 回复
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
https://esmocongress.esmo.org来源：OncLive.com · x.com